Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Andrew MorenoAggressive B-Cell Lymphoma | June 6, 2024
A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T.
Read More
Lakshmi Nayak, MDAggressive B-Cell Lymphoma | June 4, 2024
These findings concern axi-cel use in relapsed and refractory primary and secondary disease.
Melissa BadamoAggressive B-Cell Lymphoma | June 3, 2024
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Francesco Bertoni, MD, PhDAggressive B-Cell Lymphoma | April 30, 2024
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Sarah ValentineAggressive B-Cell Lymphoma | March 26, 2024
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
Melissa BadamoAggressive B-Cell Lymphoma | May 21, 2024
The approval was declined due to the enrollment status of the confirmatory trials.
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Blood Cancer TalksBlood Cancer Talks | March 20, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Patrick DalyAggressive B-Cell Lymphoma | December 16, 2023
The study included 16 baseline and 18 post-infusion tumor samples from 26 patients.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
Leah SherwoodAggressive B-Cell Lymphoma | December 14, 2023
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
Blood Cancers Today Staff WritersAggressive B-Cell Lymphoma | February 2, 2024
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
Kerri FitzgeraldAggressive B-Cell Lymphoma | December 13, 2023
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Jay Spiegel, MDAggressive B-Cell Lymphoma | December 14, 2023
Dr. Spiegel shared five-year data from a retrospective study of 298 patients with LBCL who received axi-cel.
Peter Riedell, MDAggressive B-Cell Lymphoma | December 12, 2023
Polatuzumab-based bridging was associated with high overall response rate and complete response rate.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
The SEER database was used to examine disparities in incidence and survival outcomes between different races.
Alison Sehgal, MDAggressive B-Cell Lymphoma | December 12, 2023
Liso-cel "should continue to be a really good option for these older patients," Dr. Sehgal said.
Julie Vose, MD, MBAAggressive B-Cell Lymphoma | December 11, 2023
Julie Vose, MD, MBA, discussed the use of epcoritamab in patients with diffuse large B-cell lymphoma (DLBCL).
Editorial Board